Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

571

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]